All In Biotech

Drug Trial Radar · NCT07400003

Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

A Randomized, Double-Blind, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Different Doses of a Lyophilized Herpes Zoster Virus mRNA Vaccine in Adults Aged 40 Years and Older

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 519 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

519

Planned (sponsor's estimate)

Start

Jan 6, 2026

Primary completion

May 31, 2026

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.

Conditions

  • Herpes Zoster
  • mRNA Vaccine

Interventions

  • Low-dose experimental vaccineBiological

    Lyophilized herpes zoster virus mRNA vaccine

  • High-dose experimental vaccineBiological

    Lyophilized herpes zoster virus mRNA vaccine

  • Active-controlled vaccine ABiological

    herpes zoster attenuated live vaccine, lyophilized

  • Active-controlled vaccine BBiological

    Shingrix®

  • Placebo groupOther

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of adverse reactions within 30 daysTime frame: 0~30 days after each dose vaccination
  2. Seroconversion rate of gE antibodyTime frame: Day 30 after two doses
  3. Geometric mean concentration (GMC) of gE antibodyTime frame: Day 30 after two doses

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention

    Xinjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.